ModifiedCapital BluecrossPolicy MP 4.043

Treatments of the Prostate (Focal, Water Vapor, Aquablation, and Hydrogel Spacer)

This medical policy governs coverage stance for focal prostate cancer treatments, transurethral water vapor thermal therapy, transurethral waterjet ablation (aquablation), and hydrogel rectal spacers for members of Capital BlueCross programs to which the policy applies.

Policy Summary

PayerCapital Bluecross

PolicyTreatments of the Prostate (Focal, Water Vapor, Aquablation, and Hydrogel Spacer)

Policy CodePolicy MP 4.043

Change TypeInvestigational reclassification + coding updates

Effective Date1/1/2026

Next Review DateN/A

Key ActionObtain prior authorization per product-specific rules and verify member benefits before scheduling investigational-designated prostate procedures.

SourceLink

POLICY UPDATE CHANGES

Policy statement changed from MN to INV for water vapor thermal therapy and hydrogel rectal spacer; all policy language changed from not medically necessary to investigational.

Added codes 0941T-0943T, 51721, 53865, 53866, 55881, 55882 effective 01/01/2025.

Prostatic Urethral Lift and Nitinol Device (and associated procedure codes) were removed and placed into their own policies (MP 1.147 and MP 1.164).

4investigational therapy categories

10/31/2024major review date

01/01/2025coding effective

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

14.3NNT (rectal toxicity)

288,300estimated new US cases cited

Coverage determinations and evidence conclusions

Focal therapy — investigational

Covered when ALL of the following are met:

Investigational stance: Use of any focal therapy modality to treat individuals with localized prostate cancer is investigational.

Insufficient evidence to support a general conclusion about health outcomes or benefits.

Transurethral water vapor thermal therapy — investigational

Covered when ALL of the following are met:

Investigational stance: Transurethral water vapor thermal therapy (eg, Rezūm) is considered investigational as a treatment of benign prostatic hyperplasia (BPH).

Evidence includes a single sham-controlled RCT with 3-month primary endpoint and 5-year uncontrolled follow-up; limitations include small sample size, limited long-term blinding, and lack of comparison to TURP.

Transurethral waterjet ablation (aquablation) — investigational

Covered when ALL of the following are met:

Investigational stance: Transurethral waterjet ablation (Aquablation/Aquabeam) is considered investigational as a treatment of benign prostatic hyperplasia (BPH).

Evidence includes a noninferiority RCT versus TURP with 5-year follow-up showing noninferior IPSS improvement but overall evidence judged imprecise and insufficient to determine net health outcome.

Hydrogel rectal spacer — investigational

Covered when ALL of the following are met:

Investigational stance: Hydrogel rectal spacer (eg, SpaceOAR, Barrigel, BioProtect Balloon) is considered investigational for all indications.

Pivotal RCTs and observational studies show reduced rectal dose and decreased late rectal toxicity (NNT reported), but evidence limitations and procedural risks make net health outcome uncertain.

Focal therapy — evidence conclusion

Focal treatments for primary localized prostate cancer:

Focal therapy evidence summary: Evidence is heterogeneous and consists largely of observational studies, registries, and a systematic review; no prospective comparative trials versus standard treatments (radical prostatectomy, external-beam radiotherapy, or active surveillance) were identified. Methods and patient selection are not standardized, outcomes are inconsistently reported, and follow-up is generally short and underpowered to assess survival; overall evidence is insufficient to determine net health benefit.

Adverse event rates may be lower than radical treatments, but quality and consistency of data are inadequate to support coverage.

Water vapor therapy — evidence conclusion

Transurethral water vapor thermal therapy (Rezum):

Water vapor therapy evidence: A single 3-month, sham-controlled randomized trial (n≈197) with up to 5-year uncontrolled follow-up demonstrated short-term symptom improvement versus sham and sustained improvements to 5 years; limitations include small sample size, limited long-term blinding, and absence of direct comparison to TURP. Overall evidence is insufficient to determine an improvement in the net health outcome.

No adverse effects on sexual function were observed in trial reports, but comparative effectiveness versus standard surgical options remains unestablished.

Aquablation — evidence conclusion

Aquablation (Aquabeam):

Aquablation RCT: One noninferiority randomized trial (187 patients) comparing aquablation to TURP with 5-year follow-up showed noninferior improvement in IPSS at 6 months and similar long-term outcomes; a lower rate of persistent operative complications at 3 months favored aquablation, but overall estimates are imprecise and supportive comparative data are limited. Evidence is insufficient to conclude improved net health outcome.

Additional trials and data on comparative adverse events are needed.

Hydrogel spacer — evidence conclusion

Hydrogel spacer for prostate radiotherapy:

Hydrogel spacer evidence: Pivotal RCTs (SpaceOAR with 3-year follow-up; Barrigel up to 6 months), observational studies, and systematic reviews show reduction in rectal radiation dose and a statistically significant decrease in Grade ≥1 late rectal toxicity (NNT ~14.3) and improvements in patient-reported rectal and urinary quality-of-life measures; however, trials lacked blinding, excluded higher-risk patients, and there were few clinically significant Grade ≥2 events (NNT for Grade 2 toxicity ~68). Overall evidence is insufficient to conclusively determine net health outcome and benefits must be weighed against procedural risks.

Further study needed to define which patients derive clinically meaningful benefit.

Investigational/Not Medically Necessary Procedures

Coverage stance and evidence summary from document extract

Investigational procedures: Aquablation (CPT 52597, C2596), radiofrequency water vapor/steam therapy (CPT 53854), hydrogel therapy (CPT 55874), and specified focal therapy procedure codes (including the listed T-code mappings) are designated investigational in this policy extract.

Providers should expect investigational designation may lead to noncoverage or require prior authorization review.

Evidence and Guidelines

Evidence and guideline context cited for minimally invasive BPH therapies:

Supporting evidence: Randomized controlled trials, multicenter prospective studies, Cochrane reviews, FDA de novo device classification, and guideline statements (AUA, NICE, NCCN, UpToDate) are cited supporting the clinical literature for Rezūm (water vapor) and Aquablation, but limitations in trial design and comparative data are noted.

These references provide context for review but do not establish coverage criteria in this policy excerpt.

Investigational Procedures

Policy coverage stance updated for specific procedures:

Investigational classification: Water vapor thermal therapy and hydrogel rectal spacer were reclassified from Not Medically Necessary to Investigational (INV) during the major review dated 10/31/2024.

Coding and investigational tables were updated in the administrative changes accompanying the major review.

Hydrogel Rectal Spacer is designated investigational for all indications. The available evidence is considered insufficient to support a general conclusion about clinical benefit for any use of this technology.

None stated specifically in this portion of the document regarding additional exclusionary language for hydrogel spacers beyond the investigational designation and the described clinical context of prostate cancer staging and diagnosis.

Procedures and procedure codes explicitly labeled investigational in the policy (for example, the focal treatment T-code mappings and the listed CPT/HCPCS codes for aquablation, water vapor thermal therapy, and hydrogel therapy) are treated as investigational services and are effectively excluded from coverage when billed under those investigational codes.

Content and code sets related to the Prostatic Urethral Lift and the Nitinol Device (iTind) were removed from this policy and have been relocated to separate policies (see MP 1.147 and MP 1.164) effective with the administrative revisions described in the policy history.

This policy addresses the coverage stance for several prostate therapies, including focal therapy modalities for localized prostate cancer, transurethral water vapor thermal therapy for benign prostatic hyperplasia (BPH), transurethral waterjet ablation (aquablation) for BPH, and hydrogel rectal spacers used in conjunction with prostate radiotherapy.

For the therapies listed above, the policy concludes that current evidence is heterogeneous and limited; randomized trials and observational studies exist for some interventions but overall are insufficient to determine improvements in net health outcomes. Consequently, these technologies are designated investigational due to insufficient evidence to support routine coverage.

Specifically, the policy designates aquablation (52597, C2596), radiofrequency water vapor/steam therapy (53854), hydrogel therapy (55874), and the focal therapy T-code mappings (e.g., .0601T, .0655T, .0739T, .0941T, .0942T, .0943T, .0950T/related mappings) as investigational.

On major review (10/31/2024) the policy replaced prior wording of 'not medically necessary' for certain items with an investigational classification, updating the policy language and coding tables accordingly.

Codes and coding guidance

FDA product codes and device clearances mentionedmixed

LLZ	FDA product code(s) referenced for focal laser devices
GEX	FDA product code referenced for laser devices
FRN	FDA product code referenced for laser devices
GEH	FDA product code for cryoablation devices
GEI	FDA product code for radiofrequency ablation devices
FTC	FDA product code for photodynamic therapy devices/drugs
NanoKnife (K102329)	Device clearance reference for irreversible electroporation system (NanoKnife)

Investigational when used to describe Focal Treatments for Prostate CancermixedExperimental

51721
.0601T	mapped to 55877
.0655T	mapped to 55880
.0739T	mapped to 55881
.0941T	mapped to 55882
.0942T	mapped to 55899*
.0943T
.0950T
55877
55880

1–10 of 13

1/2

Investigational focal treatment procedure codes (T-code mappings)mixedNot Covered

51721	Procedure code referenced in mapping to T-codes
.0601T	mapped to 55877 per document
.0655T	mapped to 55880 per document
.0739T	mapped to 55881 per document
.0941T	mapped to 55882 per document
.0942T	mapped to 55899* per document
.0943T	listed without mapping in document
.0950T	listed without mapping in document

Investigational procedure codesCPT | HCPCSNot Covered

52597	Aquablation — listed as investigational
C2596	Aquablation-related code — listed as investigational
53854	Radiofrequency water vapor (steam) thermal therapy — listed as investigational
55874	Hydrogel therapy — listed as investigational

Updated/Investigational and newly added procedure codesCPT

0600T	listed in investigational table (prior)
0601T	listed in investigational table (prior)
0739T	listed in investigational table (prior)
53854	moved to investigational table
55874	moved to investigational table (previously added)
0941T	added
0942T	added
0943T	added
51721	added
53865	added

1–10 of 16

1/2

ICD codes updatedICD-10

N13.8	ICD code added/updated
R33.8	ICD code added/updated
R39.15	ICD code added/updated
R39.16	ICD code added/updated

Actions, prior authorization, and documentation

Documentation Required

Program applicability and documentation

This policy may only apply to certain Capital Blue Cross programs and products. Verify member benefit plan applicability and eligibility prior to scheduling services and document program-specific coverage rules in the medical record.

Confirm member benefit program and eligibility on date of service.
Refer to program-specific policy variations (including FEP) prior to authorization.

Prior Authorization

Prior authorization and product variations

Prior authorization may be required for procedures addressed in this policy depending on the member’s benefit plan. Providers should check prior authorization requirements with Capital Blue Cross and submit requests when required. Product variations (listed above) may affect prior authorization rules.

Submit prior authorization when required by the member’s benefit plan.

Clinical background and scope

Prostate cancer is a common, heterogeneous disease, predominantly affecting older men. Screening with prostate-specific antigen (PSA) and diagnostic biopsy guide staging and management. Focal treatment approaches seek to ablate discrete tumor foci within the prostate to reduce disease progression while preserving surrounding glandular tissue and reducing morbidity compared with radical therapies, but evidence on long-term oncologic outcomes and standardized selection methods is limited.

Definitions and modality descriptions

Focal treatment definition

DefinitionTreatment that targets and ablates cancerous lesions within the prostate while preserving uninvolved glandular tissue to minimize morbidity from radical treatments

GoalMinimize risk of early tumor progression while preserving erectile, urinary, and rectal function by reducing damage to neurovascular bundles, external sphincter, bladder neck, and rectum

ApproachAblation of high‑risk tumor foci and retention of uninvolved parenchyma as a middle ground between active surveillance and radical therapy

Ablative modalities

Included modalitiesFocal laser ablation; high‑intensity focused ultrasound (HIFU); cryoablation; radiofrequency ablation (RFA); photodynamic therapy; irreversible electroporation

Common technique

Policy changes and administrative updates

2025-01-01administrative_coding_update

Added procedure codes 0941T–0943T, 51721, 53865, 53866, 55881, and 55882 as part of an administrative coding update effective January 1, 2025.

2024-10-31major_review_material_changeLatest

Major review reclassified transurethral water vapor thermal therapy (Rezum) and hydrogel rectal spacer from Not Medically Necessary to Investigational and moved codes 53854 and 55874 to the investigational table; added codes 0600T, 0601T, and 0739T to the investigational table.

Policy Summary

PayerCapital Bluecross

PolicyTreatments of the Prostate (Focal, Water Vapor, Aquablation, and Hydrogel Spacer)

Policy CodePolicy MP 4.043

Change TypeInvestigational reclassification + coding updates

Effective Date1/1/2026

Next Review DateN/A

Key ActionObtain prior authorization per product-specific rules and verify member benefits before scheduling investigational-designated prostate procedures.

SourceLink

On This Page

Document medical necessity and relevant prior conservative therapies when requesting authorization.

Prior Authorization

Investigational procedure prior authorization recommended

Providers are advised to request prior review before performing investigational procedures described in this policy. When feasible, obtain prior authorization or an administrative coverage determination to reduce risk of claim denial.

Request prior review/authorization for investigational procedures (e.g., focal therapy, aquablation, water vapor thermal therapy, hydrogel spacer).
Provide complete clinical documentation with the request to support medical necessity and rationale for investigational use.

Denial Risk

Investigational — potential denial

The procedures and codes listed in this policy are classified as investigational. Claims submitted for investigational therapies may be denied when billed under standard medical benefits.

Focal treatments for prostate cancer (investigational) may be denied.
Transurethral water vapor thermal therapy and aquablation for BPH (investigational) may be denied.
Hydrogel rectal spacer (investigational) may be denied.

Note

Coding does not equal coverage

Identification of a billing or procedure code in the policy does not guarantee coverage. Coverage determinations depend on the member’s benefit plan, eligibility on the date of service, and whether services are medically necessary.

Use the member’s contract and benefit terms to confirm coverage.
A code appearing in the Coding Information section is informational and not an authorization of payment.

Denial Risk

Investigational procedures may be denied

Specific investigational procedures addressed in this policy may be denied if billed under standard benefits without prior review demonstrating medical necessity or approved exceptions.

Aquablation, water vapor thermal therapy, and hydrogel spacer procedures are listed as investigational and may be denied.
Focal prostate cancer treatments are investigational and may be denied.

Billing Rule

Focal treatment investigational codes

Certain focal treatment–related procedure codes are listed as investigational; billing these codes without an approved coverage determination may result in denial.

Investigational/focal treatment codes include (examples from coding table): 51721 and associated temporary codes (0601T, 0655T, 0739T, 0941T–0943T, 0950T) where applicable.
Aquablation and water vapor thermal therapy codes (e.g., 52597, 53854, C2596) and hydrogel code 55874 are classified investigational in this policy.

Documentation Required

Documentation of medical necessity and eligibility

Document medical necessity, prior conservative therapies, and member eligibility when submitting prior authorization requests or claims. Ensure the medical record supports the clinical indications and rationale for the requested procedure.

Document trials of medical therapy (alpha-blockers, 5-alpha-reductase inhibitors, anticholinergics, PDE5 inhibitors) where applicable before surgical/minimally invasive options.
Record member eligibility and benefit plan details on date of service.
Include relevant imaging, prior treatments, symptom impact on quality of life, and rationale for procedural selection in the authorization request.

Note

Consideration of standard therapy first

Consider established standard surgical management (for example, TURP) and other guideline-recommended therapies before pursuing investigational or less-established surgical options for BPH.

Evaluate and document that standard therapies (medical therapy and TURP when indicated) were considered or attempted prior to investigational procedures.
Include rationale why an investigational approach is selected over standard therapy in the record and prior authorization submission.

Note

Supporting clinical references

References supporting clinical rationale and policy determinations are provided in the References section. Use current clinical guidelines and primary literature to substantiate requests for coverage when applicable.

Key references include UpToDate (medical treatment of BPH), FDA device decisions (Aquabeam, Rezūm), Cochrane reviews, AUA guideline updates, and randomized trials of aquablation and water vapor therapy.
Include pertinent citations when submitting clinical rationale for coverage of specific cases.

Billing Rule

Coding and claims documentation

Use the policy's Coding Information section and the member’s benefit terms when preparing claims. Administrative code updates (effective dates noted in Policy History) may change which codes appear in the investigational list.

The identification of a code does not imply coverage; confirm code applicability to the member’s plan.
Be aware of administrative code changes effective 01/01/2025 and subsequent updates described in the Policy History.
Provide documentation to support billing under the appropriate code and rationale if requesting an exception.

Placement of a needle probe into the tumor volume followed by delivery of energy to destroy tissue in a controlled manner

GuidanceMost methods rely on ultrasound guidance to the tumor focus; focal laser ablation uses MRI guidance

Benign prostatic hyperplasia (BPH)

DefinitionHistologic increase in stromal and glandular epithelial cells in the prostate transition zone that may cause prostate enlargement and bladder outlet obstruction

Clinical presentationMay lead to lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, weak stream, straining, and nocturia

Management contextMedical therapies (alpha‑blockers, 5‑alpha‑reductase inhibitors, anticholinergics, PDE‑5 inhibitors) are considered first; persistent symptoms despite medical therapy may prompt surgical options such as TURP

Transurethral water vapor thermal therapy (Rezum)

ProcedureMinimally invasive transurethral procedure using radiofrequency‑generated water vapor (~103°C) delivered convectively to ablate prostate tissue

Intended useInvestigated as a minimally invasive alternative to TURP for treatment of LUTS due to BPH

MechanismUses convective rather than conductive heat transfer to cause tissue ablation

Aquablation (Aquabeam)

ProcedureRobotic transurethral waterjet ablation that uses a pressurized fluid jet to cut and remove prostate tissue (Aquabeam)

RoleInvestigated as a minimally invasive alternative to TURP for LUTS due to BPH

Regulatory noteAquabeam received FDA de novo classification (see policy references)

Hydrogel spacer (SpaceOAR, Barrigel, BioProtect Balloon)

DefinitionImplanted biodegradable material placed in the perirectal space to temporarily separate the anterior rectal wall from the prostate during radiotherapy

ExamplesSpaceOAR (Augmenix), Barrigel Injectable Gel (Palette Life Sciences), BioProtect Balloon Implant (BioProtect, Ltd)

Intended benefitReduce radiation dose to the anterior rectum during prostate radiotherapy

Focal therapy (alternate location)

ScopeFocal therapy denotes targeted ablation modalities (HIFU, cryoablation, laser, RFA, photodynamic therapy, irreversible electroporation) used to treat localized prostate cancer foci

Evidence characteristicsAvailable evidence is heterogeneous (observational studies, systematic reviews); prospective comparative evidence vs standard treatments is lacking

Clinical intentAim to reduce treatment morbidity compared with radical therapies while treating lesions at high risk of progression

Transurethral water vapor thermal therapy (Rezūm) — trials and outcomes

Key trialsReZūm: randomized, sham‑controlled trial with 3‑month primary endpoint and up to 5‑year follow‑up reporting short‑term symptom improvement and sustained benefits to 5 years

LimitationsTrials limited by small sample sizes, limited blinding, and lack of head‑to‑head comparison with TURP in some studies

Outcomes reportedSymptom improvement at early time points and patient‑reported preservation of sexual function in follow‑up publications

Aquablation — FDA de novo and trial evidence

Regulatory statusAquabeam was granted FDA de novo classification (DEN170024) and randomized trials compare Aquablation to TURP

Key evidenceOne noninferiority randomized trial (WATER) with up to 5‑year follow‑up showed noninferior IPSS improvement and similar long‑term outcomes; safety signal favored aquablation for some early complications but evidence judged imprecise

Systematic reviewsMeta‑analyses and Cochrane reviews summarized effectiveness across prostate anatomies and trial follow‑up intervals

Hydrogel Spacer — radiotherapy benefit details

Intended radiotherapy benefitHydrogel spacers are intended to increase distance between prostate and rectum to reduce rectal radiation dose and decrease rectal toxicity during prostate radiotherapy

Regulatory clearancesSpaceOAR cleared via De Novo (DEN140030); Barrigel and BioProtect Balloon approved via PMA (K220641, K222972)

EvidencePivotal RCTs and meta‑analyses report reduced rectal dosimetry and statistically significant decreases in late rectal toxicity and improvements in patient‑reported outcomes, though limitations remain

Aquablation — supplementary description

DescriptionAquablation is a robotic transurethral waterjet ablation that mechanically removes prostate tissue using a high‑velocity fluid jet

Evidence summaryRandomized controlled trials (including WATER) with 1‑, 3‑, and 5‑year outcomes have been published comparing aquablation with TURP; systematic reviews and guideline statements cited

Clinical considerationsTrials show noninferior symptom relief versus TURP but evidence considered imprecise and insufficient to conclude net health outcome improvement in this policy

2025-01-01administrative_coding_update

Administrative update adding codes 0941T–0943T, 51721, 53865, 53866, 55881, and 55882 effective January 1, 2025 (coding tables updated).